Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Must have received: systemic therapy — for CLL

Previously untreated patients with RT must have received prior therapy for CLL

Cannot have received: anti-CD20 monoclonal antibody

Exception: for non-malignant indication, including for autoimmune phenomenon

Prior receipt of anti-CD20 monoclonal antibody therapy for non-malignant indication, including for autoimmune phenomenon

Cannot have received: systemic therapy

Prior receipt of systemic therapy for CLL/SLL

Cannot have received: BTK inhibitor

Exception: Patients who experienced a major bleeding event or grade ≥3 arrythmia on prior treatment with a BTK inhibitor

Patients who experienced a major bleeding event or grade ≥3 arrythmia on prior treatment with a BTK inhibitor

Cannot have received: stem cell transplant

Exception: within 60 days of first dose of study drugs

History of allogeneic or autologous stem cell transplant (SCT) within 60 days of first dose of study drugs

Cannot have received: CAR-T cell therapy

Exception: within 60 days of first dose of study drugs

chimeric antigen receptor-modified T cell (CAR-T) therapy within 60 days of first dose of study drugs

Cannot have received: immunoconjugated antibody

Exception: within 10 weeks prior to randomization

Immunoconjugated antibody treatment within 10 weeks prior to randomization